Takeda Pharmaceutical Company Limited

TKPHFOTCHealthcare● Active

$32.60

+$2.13(+6.99%)

Market Cap$51.5B

P/E Ratio—

52W High$39.2

52W Low$26.33

Avg Volume6K

Open$32.60

Beta0.09

Free Cash Flow Financials Revenue

Takeda Pharmaceutical Company Limited (TKPHF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

TKPHF · free cash flow · updated Jun 9, 2026

Core FCF metrics

TKPHF · FCF · TTM · margin & CAGR

Free cash flow was $767.51B for FY2026 (fiscal year ending 2026-03-31), up 13.3% year-over-year The FCF margin was 16.9%. Five-year CAGR stands at -0.2%.

FY2026 Free Cash Flow$767.51B▲ +13.3% YoY

Trailing 12M (TTM)$767.04Btrailing 4 quarters sum

FCF Margin16.9%$767.51B ÷ revenue

3-Year CAGR+30.7%FY2023 → FY2026

5-Year CAGR-0.2%FY2021 → FY2026

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

TKPHF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2026Latest$944.62B(177.11B)$767.51B▲ +13.3%16.9%

FY2025$1.06T(379.63B)$677.56B▲ +187.6%14.8%

FY2024$716.34B(480.73B)$235.61B▼ 31.4%5.5%

FY2023$977.16B(633.69B)$343.47B▼ 63.3%8.5%

FY2022$1.12T(186.04B)$937.07B▲ +21.0%26.3%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

TKPHF · P/FCF · FCF yield · FCF per share

Takeda Pharmaceutical Company Limited (TKPHF) trades at a FCF yield of 9.95% and a price-to-free-cash-flow ratio of 0.1x. FCF per share stands at $486.99, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

9.95%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$486.99

TTM FCF ÷ Shares Outstanding

Price / FCF

x0.1

Share Price ÷ FCF per Share

EV / FCF (TTM)

x15.5

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2026 · 2026-03-31

Cash flow statement summary

TKPHF · cash flow statement · operating / investing / financing

For FY2026, Takeda Pharmaceutical Company Limited generated $944.62B in operating cash flow and spent 177.11B in capital expenditures, yielding $767.51B in free cash flow.

Operating Activities

+$944.62B

Cash from core business operations

2026-03-31

Investing Activities

−$390.24B

CapEx, acquisitions & investments

2026-03-31

Financing Activities

−$377.80B

Buybacks, dividends & debt

2026-03-31

FCF FormulaOperating CF ($944.62B) − |CapEx| (177.11B) = FCF ($767.51B)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

TKPHF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Takeda Pharmaceutical Company LimitedYOU

TKPHF

$767.51B+13.3%16.9%

100%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Takeda Pharmaceutical Company Limited (TKPHF) reported free cash flow of $767.51B for FY2026 (fiscal year ending 2026-03-31), up 13.3% year-over-year. The FCF margin was 16.9%.

Based on available data, Takeda Pharmaceutical Company Limited has maintained positive free cash flow for at least 14 fiscal year(s). FCF peaked at $937.07B in FY2022. The 5-year CAGR stands at -0.2%.

Takeda Pharmaceutical Company Limited's FCF yield is 9.95% and price-to-FCF ratio is 0.1x for FY2026, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

TKPHF free cash flow · 8 questions

Takeda Pharmaceutical Company Limited free cash flow was $767.51B for FY2026, up 13.3% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $767.04B.

TKPHF free cash flowTKPHF FCFTKPHF FCF 2026TKPHF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Takeda Pharmaceutical Company Limited · Takeda Pharmaceutical Company Limited SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026